These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34134766)

  • 1. SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma.
    Wu J; Zhang M; Faruq O; Zacksenhaus E; Chen W; Liu A; Chang H
    Biomark Res; 2021 Jun; 9(1):48. PubMed ID: 34134766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma.
    Faruq O; Zhao D; Shrestha M; Vecchione A; Zacksenhaus E; Chang H
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma.
    Zhang L; Rastgoo N; Wu J; Zhang M; Pourabdollah M; Zacksenhaus E; Chen Y; Chang H
    Cancer Lett; 2020 Jun; 480():29-38. PubMed ID: 32220540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma.
    Rastgoo N; Wu J; Liu A; Pourabdollah M; Atenafu EG; Reece D; Chen W; Chang H
    Haematologica; 2020 Dec; 105(12):2813-2823. PubMed ID: 33256380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
    Yang J; Li X; Al-Lamki RS; Southwood M; Zhao J; Lever AM; Grimminger F; Schermuly RT; Morrell NW
    Circ Res; 2010 Jul; 107(2):252-62. PubMed ID: 20522807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLIS3, a novel prognostic indicator of gastric adenocarcinoma, contributes to the malignant biological behaviors of tumor cells via modulating TGF-β1/TGFβR1/Smad1/5 signaling pathway.
    Zhang Y; Wang B; Song H; Han M
    Cytokine; 2023 Oct; 170():156342. PubMed ID: 37651918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of ID protein by growth and differentiation factor 5 (GDF5) through a smad-dependent and MAPK-independent pathway in HUVSMC.
    Chen X; Zankl A; Niroomand F; Liu Z; Katus HA; Jahn L; Tiefenbacher C
    J Mol Cell Cardiol; 2006 Jul; 41(1):26-33. PubMed ID: 16716349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK.
    Bakkebø M; Huse K; Hilden VI; Smeland EB; Oksvold MP
    BMC Immunol; 2010 Nov; 11():57. PubMed ID: 21092277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway.
    Wang Y; Dong F; Wan W; Zhang Z; Wang J; Wang H; Ke X
    Hematology; 2020 Dec; 25(1):424-432. PubMed ID: 33191863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma.
    Zhou P; Xiao M; Li W; Sun X; Bai Y; Meng F; Zhu Z; Yuan W; Sun K
    Front Pharmacol; 2022; 13():841308. PubMed ID: 35462913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.
    Yao R; Zhang M; Zhou J; Liu L; Zhang Y; Gao J; Xu K
    Cell Commun Signal; 2022 May; 20(1):73. PubMed ID: 35619182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways.
    Pannu J; Nakerakanti S; Smith E; ten Dijke P; Trojanowska M
    J Biol Chem; 2007 Apr; 282(14):10405-13. PubMed ID: 17317656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling.
    Icli B; Wara AK; Moslehi J; Sun X; Plovie E; Cahill M; Marchini JF; Schissler A; Padera RF; Shi J; Cheng HW; Raghuram S; Arany Z; Liao R; Croce K; MacRae C; Feinberg MW
    Circ Res; 2013 Nov; 113(11):1231-41. PubMed ID: 24047927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
    Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
    Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated expression of cav-1 in a subset of SSc fibroblasts contributes to constitutive Alk1/Smad1 activation.
    Haines P; Hant FN; Lafyatis R; Trojanowska M; Bujor AM
    J Cell Mol Med; 2012 Sep; 16(9):2238-46. PubMed ID: 22277251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation.
    Bariana M; Cassella E; Rateshwar J; Ouk S; Liou HC; Heller C; Colorado I; Feinman R; Makhdoom A; Siegel DS; Heller G; Tuckett A; Mondello P; Zakrzewski JL
    Mol Cancer Ther; 2022 Dec; 21(12):1798-1809. PubMed ID: 36190955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.